JOINT FAO/WHO FOOD STANDARDS PROGRAMME

CODEX ALIMENTARIUS COMMISSION
Twenty-first Session
Rome, 3 - 12 July 1995

REPORT OF THE EIGHTH SESSION OF THE
CODEX COMMITTEE ON RESIDUES OF VETERINARY DRUGS IN FOODS
Washington, D.C., USA
7 - 10 June 1994

Note: This document incorporates Codex Circular Letter 1994/17-RVDF.
The report of the Eighth Session of the Codex Committee on Residues of Veterinary Drugs in Foods is attached. It will be considered by the Twenty-first Session of the Codex Alimentarius Commission which is scheduled to be held in Rome from 3 - 12 July 1995.

PART A. MATTERS FOR ADOPTION BY THE 21ST SESSION OF THE CODEX ALIMENTARIUS COMMISSION

The following matters will be brought to the attention of the 21st Session of the Codex Alimentarius Commission for adoption:

1. DRAFT MAXIMUM RESIDUE LIMITS FOR VETERINARY DRUGS AT STEP 8; ALINORM 95/31, paras. 44-45, 47-48 and Appendix II

2. DRAFT REVISED CRITERIA FOR THE INCLUSION IN, OR EXCLUSION FROM, THE PRIORITY LIST; ALINORM 95/31, paras. 71-72 and Appendix VIII


3. PROPOSED DRAFT MAXIMUM RESIDUE LIMITS FOR VETERINARY DRUGS AT STEP 5; ALINORM 95/31, paras. 52, 54, and Appendix IV

Governments wishing to propose amendments or to submit comments regarding the implications which the Proposed Draft Maximum Residue Limits or any provisions thereof may have for their economic interest should do so in writing in conformity with the Procedures for the Elaboration of Codex Standards and Related Texts (at Step 5) (Codex Alimentarius Procedural Manual, Eighth Edition, pp. 28-29) to the Chief, Joint FAO/WHO Food Standards Programme, FAO, Via delle Terme di Caracalla, 00100 Rome, Italy, not later than 30 April 1995.
PART B.REQUEST FOR COMMENTS

1. **RISK ANALYSIS DEFINITIONS;** ALINORM 95/31, para. 41 and Appendix IX

When discussing the implementation of risk assessment procedures, the Committee expressed concern at the fact that the use of the various expressions used by Codex in relation to risk analysis had not been harmonized. It considered that further progress would be greatly assisted by having agreed **Definitions** for Codex purposes. It recommended to the Executive Committee that such definitions be elaborated as a matter of priority in accordance with the new Accelerated Procedure with a view to their adoption by the CAC at its 21st Session. The Committee proposed that the definitions contained in Appendix IX to the present report should be sent to governments for comments and also considered by other relevant Codex Committees. It emphasized that any definitions adopted by the Commission should be harmonized to the extent possible with those of other relevant international organizations, for example, the OIE.

Governments are invited to comment on Risk Analysis Definitions, as contained in ALINORM 95/31, Appendix IX. Comments should be sent to the Chief, Joint FAO/WHO Food Standards Programme, FAO, Via delle Terme di Caracalla, 00100 Rome, Italy, **not later than 30 April 1995**.

2. **METHODS OF ANALYSIS;** ALINORM 95/31, para. 59

The Committee agreed on the recommendations made by the *ad hoc* Working Group on Methods of Analysis and Sampling that member governments continue efforts to provide validated methods to the *ad hoc* Working Group for review for those veterinary drugs with recommended MRLs.

Governments are invited to submit validated methods of analysis to the Chairman of the Working Group, Dr. Richard Ellis, Director, Chemistry Division, USDA, FSIS, Science and Technology, 300 12th Street, SW., Room 603-Annex, Washington, DC 20250, USA, **not later than 31 July 1995**.
SUMMARY AND CONCLUSIONS

The Eighth Session of the Codex Committee on Residues of Veterinary Drugs in Foods reached the following conclusions:

**MATTERS FOR CONSIDERATION BY THE COMMISSION OR ITS EXECUTIVE COMMITTEE**

- Recommended the adoption of the Draft Maximum Residue Limits for sulfadimidine, flubendazole, thiabendazole, isometamidium and bovine somatotropins at Step 8 ( paras. 44-45, 47-48);

- Recommended the adoption of the Proposed Draft Maximum Residue Limits for levamisole (muscle, kidney, fat and liver) and diminazene at Step 5 ( paras. 52, 54);

- Recommended the adoption of the revised Criteria for the Inclusion in, or Exclusion from, the Priority List to replace the earlier criteria used by the Committee (para. 72);

- Recommended to the Executive Committee that definitions used in risk analysis be elaborated as a matter of priority in accordance with the new Accelerated Procedure with a view to their adoption by the Commission at its 21st Session with the understanding that any definitions adopted by the Commission should be harmonized with those of other relevant international organizations (para. 41); and

- Agreed on a Priority List of Veterinary Drugs Requiring Evaluation or Reevaluation ( paras. 69-70).

**OTHER MATTERS OF INTEREST TO THE COMMISSION**

- Asked for an early resolution of the problem on "Role of Science and other Factors in the Codex Decision-Making Process" by the CCGP so as to allow the Commission to make a clear distinction between the role of science in the adoption of health-related standards by the Commission and the other factors influencing their acceptance by governments at the national or regional level (para. 17);

- Supported the principles of the paper entitled *Risk Assessment Procedures Used by the Codex Alimentarius Commission and its Subsidiary and Advisory Bodies* and the view that the establishment of MRLs for veterinary drugs should continue to be linked to the risk-based ADI (para. 39);

- Agreed that in principle the use of risk analysis procedures should be extended further in the Codex Procedures for the elaboration of standards (para. 40);

- Proposed that Risk Analysis Definitions be sent to governments for comments and also be considered by other relevant Codex Committees (para. 41);

- Retained the MRLs for triclabendazole at Step 7 pending future review by JECFA (para. 46);

- Retained the temporary MRL for levamisole in milk at Step 4 pending future review by JECFA (para. 52);

- Retained the temporary MRLs for spectinomycin and dexamethasone at Step 4 pending future review by JECFA (para. 55);
SUMMARY AND CONCLUSIONS (cont.d)

- Noted that chloramphenicol, flumequine and ronidazole should be added to the "inactive list" (para. 56);

- Agreed on the recommendations made by the ad hoc Working Group on Methods of Analysis and Sampling, which included (para. 59):
  - full recommendation of the multiresidue method for febantel, fenbendazole and oxfendazole for all tissues and species, and for sulfadimidine in muscle tissue; and
  - provisional recommendation of the methods for ivermectin in liver and triclabendazole in muscle, liver and kidney;

- Asked Australia to revise the document entitled Consideration of Greater Harmonization between Setting MRL and Availability of Routine Methods for the next meeting of the ad hoc Working Group on Methods of Analysis and Sampling in the light of the points raised at the Session, in particular, the concern expressed about the recommendation that JECFA should set the MRL within the sensitivity achievable (para. 60);

- Encouraged the use of ISO Layouts for Standards - Part 2: Standard for Chemical Analysis (ISO 78/2-1982) and requested that methods be submitted in this format for consideration by the Committee (para. 62);

- Requested the United States to continue the work on Compendium of Veterinary Drugs and to present a progress report at the 9th Session (para. 76);

- Accepted the offer of Australia to prepare a working paper on "Injection Site Residues of Veterinary Drugs" for consideration by the next session and requested liaison with the EC in the preparation of the paper (para. 80)

- Agreed to amend the current status of work by the CCRVDF (para. 80).
# TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Topic</th>
<th>Paragraphs</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>INTRODUCTION</strong></td>
<td>1 - 3</td>
</tr>
<tr>
<td><strong>OPENING OF THE SESSION</strong></td>
<td>4 - 6</td>
</tr>
<tr>
<td><strong>ADOPTION OF THE AGENDA</strong></td>
<td>7 - 8</td>
</tr>
<tr>
<td><strong>APPOINTMENT OF RAPPORTEUR</strong></td>
<td>9</td>
</tr>
<tr>
<td><strong>MATTERS OF INTEREST TO THE COMMITTEE</strong></td>
<td></td>
</tr>
<tr>
<td>Matters Arising from the Codex Alimentarius Commission and Other Codex Committees</td>
<td>10 - 18</td>
</tr>
<tr>
<td>Matters Arising from Activities of Other International Organizations</td>
<td>19 - 31</td>
</tr>
<tr>
<td>Report of the Forty-Second Session of JECFA</td>
<td>32 - 37</td>
</tr>
<tr>
<td><strong>IMPLEMENTATION OF RISK ASSESSMENT PROCEDURES</strong></td>
<td>38 - 41</td>
</tr>
<tr>
<td><strong>CONSIDERATION OF DRAFT MAXIMUM RESIDUE LIMITS FOR VETERINARY DRUGS</strong></td>
<td>42 - 49</td>
</tr>
<tr>
<td>At Step 7</td>
<td></td>
</tr>
<tr>
<td><strong>CONSIDERATION OF PROPOSED DRAFT MAXIMUM RESIDUE LIMITS FOR VETERINARY DRUGS</strong></td>
<td>50 - 56</td>
</tr>
<tr>
<td>At Step 4 Arising from the 42nd JECFA</td>
<td></td>
</tr>
<tr>
<td><strong>METHODS OF ANALYSIS AND SAMPLING FOR RESIDUES OF VETERINARY DRUGS</strong></td>
<td>57 - 63</td>
</tr>
<tr>
<td><strong>PRIORITY LIST OF VETERINARY DRUGS REQUIRING EVALUATION</strong></td>
<td>64 - 73</td>
</tr>
<tr>
<td><strong>PROGRESS REPORT ON COMPENDIUM OF VETERINARY DRUGS</strong></td>
<td>74 - 76</td>
</tr>
<tr>
<td><strong>OTHER BUSINESS AND FUTURE WORK</strong></td>
<td>77 - 80</td>
</tr>
<tr>
<td><strong>DATE AND PLACE OF NEXT SESSION</strong></td>
<td>81 - 82</td>
</tr>
</tbody>
</table>

# LIST OF APPENDICES

<table>
<thead>
<tr>
<th>Appendix</th>
<th>Title</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>List of Participants</td>
<td>14 - 26</td>
</tr>
<tr>
<td>II</td>
<td>Draft Maximum Residue Limits for Veterinary Drugs Advanced to Step 8</td>
<td>27 - 30</td>
</tr>
<tr>
<td>III</td>
<td>Draft Maximum Residue Limits for Veterinary Drugs Retained at Step 7</td>
<td>31</td>
</tr>
<tr>
<td>IV</td>
<td>Proposed Draft Maximum Residue Limits for Veterinary Drugs Advanced to Step 5</td>
<td>32 - 33</td>
</tr>
<tr>
<td>V</td>
<td>Proposed Draft Maximum Residue Limits for Veterinary Drugs Retained at Step 4</td>
<td>34 - 39</td>
</tr>
<tr>
<td>VI</td>
<td>List of Veterinary Drugs Evaluated by JECFA on Which No Action Has Been Taken by the Committee</td>
<td>40</td>
</tr>
<tr>
<td>VII</td>
<td>Priority List of Veterinary Drugs Requiring Evaluation or Reevaluation</td>
<td>41</td>
</tr>
<tr>
<td>VIII</td>
<td>Draft Criteria for the Inclusion in, or Exclusion from, the Priority List</td>
<td>42</td>
</tr>
<tr>
<td>IX</td>
<td>Risk Analysis Definitions</td>
<td>43</td>
</tr>
</tbody>
</table>
INTRODUCTION

1 The Codex Committee on Residues of Veterinary Drugs in Foods held its Eighth Session from 7 to 10 June 1994 in Washington, D.C., at the kind invitation of the Government of the United States of America. The Session was chaired by Dr. Stephen Sundlof, Director, Center for Veterinary Medicine, United States Food and Drug Administration. The Session was attended by 35 member countries of the Commission, 1 observer country and 7 international organizations.

2 The Session was preceded by meetings of the ad hoc Working Group on Methods of Analysis and Sampling under the Chairmanship of Dr. R. Ellis (United States) and the ad hoc Working Group on Priorities under the Chairmanship of Dr. J. Owusu (Australia). The reports of the Working Groups were presented to the Plenary under Agenda Items 8 and 9, respectively.

3 A list of participants at the Session, including members of the Secretariat, is attached to this report as Appendix I.

OPENING OF THE SESSION (Agenda Item 1)

4 Ms. Patricia Jensen, Assistant Secretary for Marketing and Inspection Services, US Department of Agriculture, addressed the Committee at the invitation of the Chairman. She emphasized the importance of establishing an international consensus in the setting of standards for foods. This was necessary to avoid international trade disputes and to maintain consumer confidence in the safety of the food supply worldwide.

5 Such harmonization had taken on an even greater importance and visibility with the GATT agreements and she expressed US support for the work of Codex in this area. The Codex Alimentarius Commission is one of three international standard-setting organizations whose health and food safety standards would serve as a key reference point in settling trade disputes. She stated that whilst the Codex system was good, it must be made better to meet the new challenges of responsibility and accountability required by the GATT agreements. The standard-setting process would need to be further streamlined to cope with the rapidly changing world and the procedures made more transparent with greater consumer involvement.

6 Ms. Jensen stressed the need to clarify the role of science in the standard-setting process in order for the Codex Alimentarius Commission to play an effective and credible role in GATT and stated that the CCRVDF deserved special credit in this area. She concluded by emphasizing the importance to the world of harmonization of food standards from both a public health and a trade point of view.

ADOPTION OF THE AGENDA (Agenda Item 2)

7 The Committee adopted the Provisional Agenda as contained in CX/RVDF 94/1.

8 The Committee agreed to the attendance of representatives of the press and that the participation would be limited to taking notes of the proceedings.

APPOINTMENT OF RAPPORTEUR (Agenda Item 3)

9 The Committee appointed Dr. J.M. Rutter (United Kingdom) to serve as Rapporteur for the Session.

MATTERS OF INTEREST TO THE COMMITTEE: (Agenda Item 4)

a) Matters Arising from the Codex Alimentarius Commission and Other Codex Committees

10 The Secretariat introduced document CX/RVDF 94/2, which summarized matters of interest to the CCRVDF arising from the 20th Session of the Codex Alimentarius Commission and other Codex Committees.
Codex Alimentarius Commission (CAC)

11 The Committee noted that the 20th Session of the CAC had adopted the first MRLs for veterinary drugs (albendazole, closantel, ivermectin, benzylpenicillin, oxytetracycline and carbadox) at Step 8. It had retained the MRLs for trenbolone acetate at Step 8 along with those for other growth-promoting hormones. The CAC had also adopted three texts at Step 8: Code of Practice for the Control and Use of Veterinary Drugs; Guidelines for the Establishment of a Regulatory Programme for the Control of Veterinary Drug Residues in Foods; and Glossary of Terms and Definitions. These adopted MRLs and other texts had been published in Codex Alimentarius, Second Edition, Volume 3, which would be sent to governments for acceptance shortly.

Codex Committee on Methods of Analysis and Sampling (CCMAS)

12 The Committee noted that the 19th Session of the CCMAS had recommended two texts for adoption by the 21st Commission: the Proposed Protocol for the Design, Conduct and Interpretation of Collaborative Studies; and the Harmonized Protocol for Proficiency Testing for Laboratory Analysis. The CCMAS had also discussed Criteria for Evaluating Acceptable Methods of Analysis for Codex purposes and had agreed that the impact of the implementation of the proposed approach on the existing Codex methods should be studied.

Codex Committee on Pesticide Residues (CCPR)

13 The Committee noted that the 26th Session of the CCPR had considered a document entitled Expression and Application of MRLs for Fat-soluble Pesticide in Animal Products and decided to bring it to the attention of the CCRVDF. The revised section of Proposals had been distributed at the meeting of the Working Group on Methods of Analysis and Sampling of the CCRVDF. The CCPR had also asked the CCRVDF to consider abamectin as the proposed MRLs being elaborated by the CCPR did not cover veterinary uses.

14 The CCPR had decided that the Recommended Method of Sampling for the Determination of Pesticide Residues in Milk, Milk Products and Eggs should be revised. The CCPR had also considered a draft paper on Pesticides Used Both as Pesticides and Veterinary Drugs prepared by Australia.

Codex Committee on General Principles (CCGP)

15 The Secretariat reported briefly on the outcome of the 11th Session of the CCGP, a summary of which was contained in document CX/RVDF 94/4 (Conference Room Document 3). The CCGP had discussed a paper prepared by the Secretariat at the request of the 20th Session of the Codex Alimentarius Commission on the Role of Science and Other Factors in the Codex Decision-Making Process (CX/GP 94/4). Some of the technical recommendations in the paper had been accepted, including the review of Codex Standards and the need to include relevant factors other than scientific knowledge at various stages of the Codex process. The need for greater transparency in Codex working procedures of expert committees had also been accepted. Other main recommendations in the paper, especially those aimed at separating scientific issues from other issues and those concerned with amendments to the adoption and acceptance procedures were not accepted. The Committee had asked the Secretariat to review in detail all of those elements in the Procedural Manual which would potentially need to be amended so as to take into account the manner by which scientific and other factors needed to be considered. A list of the Sections of the Procedural Manual potentially affected was contained in Appendix III to the CCGP report (ALINORM 95/33).

16 The CCGP had also expressed the opinion that another Session of the Committee would be required to develop specific proposals for the 21st Session of the CAC. It was reported that the Secretariat would be consulting with the Host Government authorities on this matter in the near future.

17 The CCRVDF asked for an early resolution of the problem so as to allow the Commission to make a clear distinction between the role of science in the adoption of health-related standards by the Commission and the other factors influencing their acceptance by governments at the national or regional level. The Chairman stressed that the problem was one of very high priority and that all efforts should be made to resolve the matter so as to allow the adoption in 1995 of the MRLs currently held at Step 8 by the Commission.
Codex Committee on Fish and Fishery Products (CCFFP)

18 The Committee noted that the 21st Session of the CCFFP had considered the Proposed Draft Code of Practice for the Products of Aquaculture and agreed to return it to Step 3 for redrafting. It was noted that the Proposed Draft Code of Practice would contain a Section on the use of veterinary drugs and that this would be submitted to the CCRVDF for consideration at the earliest opportunity.

b) Matters arising from Activities of Other International Organizations

AOAC International (AOAC)

19 The representative of AOAC International provided details of recent work undertaken by the organization. He drew the attention of the Committee to the development of two new programmes for validation of methods of analysis. The AOAC Test Kit Performance Testing Programme certified manufacturer claims regarding the test kit. This involved expert review of performance characteristics developed by the manufacturer and independent performance testing by at least one other laboratory. The AOAC Peer-Verified Methods Programme formed the second new category of validation by the organization. The procedure involved in-house validation followed by validation in at least one other laboratory.

20 The representative also reported that AOAC International had continued its collaboration with ISO and IUPAC on the development of laboratory performance Protocols. AOAC International had adopted 95 methods as first action and 84 as final action during the period of 1992-1993.

Consultation Mondiale de l’Industrie de la Santé Animale (COMISA)

21 The representative of COMISA stated that COMISA had actively supported the work of the Committee since 1986 by acting as an observer to the CCRVDF and supporting the provision of scientific data to JECFA. Since the last meeting of the Committee, COMISA had welcomed the definition of data requirements for microbiological endpoints and supported the proposed new initiative on harmonization of veterinary drug regulatory requirements adopted at the ITCRVD meeting in Paris in May 1994.

European Community (EC)

22 The representative of the EC presented information on progress in the establishment of MRLs for residues of veterinary medicinal products since Council Regulation (EEC) 2377/90 had entered into force on 1 January 1992. About 50 substances had been reviewed, of which 25 had been assigned final MRLs and the other 25 provisional MRLs. All other substances used in authorized products had to be classified according to the Council Regulation before 1 January 1997 if their continued use in food-producing animals was to be permitted.

23 The Committee was informed of the establishment of the European Agency for the Evaluation of Medicinal Products, which would become operational on 1 January 1995. Through a centralized procedure, Community-wide marketing authorizations would be granted by the European Commission on the scientific advice of the Agency. This procedure would be obligatory for products derived by biotechnology and for performance enhancers and, among other criteria, optional for products derived by high technologies and for veterinary medicinal products containing new active ingredients intended for use in food-producing animals.

24 The Observer further informed the Committee that the Community Reference Laboratories for the Research of Residues, which had been officially approved in 1991, had started their activities in August 1993. In close collaboration with the national reference laboratories within the EC, the improvement and harmonization of the methods of analysis, as well as the coordination of research in new methods had been regarded as urgent priorities.
International Dairy Federation (IDF)

25 The representative of the IDF informed the Committee of activities being undertaken by Group E503 in the IDF. Group E503 considered and validated methods for antibiotics, sulfonamides and inhibitors in raw milk. The Group had organized workshops and symposia on the detection of antibiotics and other antimicrobial inhibitors in milk and milk products (Workshop on Antibiotics and Other Microbial Inhibitors in Raw and Heat-treated Milk, December 1993, Denmark and Symposium on Antimicrobial Drugs, August 1995, Germany). Intercomparison studies were carried out and evaluated as part of a validation programme for detection methods. The representative informed the Committee that the IDF No 528:1991, collection of methods available for the detection of antibiotics and inhibitors, was being continuously revised and updated.

International Organization of Consumers Unions (IOCU)

26 The representative of IOCU welcomed the improved transparency and efforts to increase consumer involvement in Codex procedures. Both initiatives would contribute to the technical quality of Codex standards and to consumer confidence in food produced to meet those standards.

Office Internationale des Epizooties (OIE)

27 The OIE Representative reported that the OIE had continued to provide programmes of training and information relating to veterinary drugs. The OIE newsletter on veterinary drug registrations was published twice a year in English, French and Spanish. The training programmes included seminars and workshops dedicated to the veterinary drug legislation and regulation at both the national and regional levels. Such seminars had recently been held in Bamako (Mali), Rabat (Morocco), Bogota (Colombia), Bogor (Indonesia) and Harare (Zimbabwe).

28 The OIE had responded to requests from interested countries on the transfer of technologies related to the pharmaceutical quality control of veterinary drugs. Contacts had been made with laboratories potentially capable of undertaking such controls, most notably in Mali, Côte d'Ivoire, Niger, Morocco, Colombia, Thailand, Indonesia and Zimbabwe.

International Technical Consultation on the Registration of Veterinary Drugs (ITCRVD)

29 The 7th ITCRVD was held at the Headquarters of OIE in Paris in May 1994. More than 90 participants representing 43 countries participated. Several recommendations were adopted directed to current important questions related to veterinary drug registration such as: good laboratory practices; inspection of laboratories; distribution; registration agencies; data banks; and environmental hazards. Two workshops were organized to consider the OIE programme relative to veterinary drug legislation and the control of veterinary drug residues in foods. A joint ITCRVD/Industry session was devoted to the international harmonization of scientific requirements for veterinary drug registration. An important recommendation adopted during this session invited the OIE to establish an ad hoc group to prepare proposals in this regard.

Pan American Health Organization (PAHO)

30 The representative of PAHO reported its activities concerning food protection conducted within the framework of the Regional Program of Technical Cooperation in Food Protection, approved by the Pan American Sanitary Conference and the Ministers of Health and Agriculture in the region of the Americas. The PAHO programme was administered by the Veterinary Public Health Program. Implementation was accomplished through 14 Veterinary Public Health and Food Protection Consultants, located in several countries. The Pan American Institute for Food Protection and Zoonoses - INPPAZ - provided laboratory support for food protection and zoonoses activities. Under the coordination of the Veterinary Public Health Program, a Regional Advisor acted as the focal point for the activities in food protection. The representative further informed the Committee of specific food protection activities including integrated programmes of food protection, strengthening of laboratory and inspection services, and epidemiological surveillance of foodborne diseases.
- UPDATE ON THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS RELATED TO SANITARY AND PHYTOSANITARY MEASURES AND THE AGREEMENT ON TECHNICAL BARRIERS TO TRADE

31 The Secretariat introduced document CX/RVDF 94/4, which contained a brief reference to the texts of the Agreement on the Application of Sanitary and Phytosanitary Measures and the Agreement (1994) on Technical Barriers to Trade. The texts of these Agreements as adopted in the Final Act of the Uruguay Round in December 1993 had been circulated by the Codex Secretariat to Contact Points under cover of Circular Letter 1994/3-GEN. It was noted that these texts had been the subject of legal revisions, not affecting the substance of the Agreements, prior to the final signing of the Uruguay Round Final Act in Marrakesh in April 1994. The Committee noted that the implications of the Final Act Agreements in relation to the work of Codex would be the subject of discussions at the Executive Committee's 41st Session.

c) Report of the Forty-Second Session of JECFA

32 The Committee had before it a summary of the report of the Forty-second meeting of the Joint FAO/WHO Expert Committee on Food Additives (CX/RVDF 94/7). The FAO and WHO Joint Secretaries of JECFA summarized the results.

33 Nine veterinary drugs were on the agenda for evaluation. Acceptable daily intakes (ADIs) and maximum residues limits (MRLs) were allocated to diminazene, levamisole and sulfadimidine. ADIs and temporary MRLs were allocated to dexamethasone and spectinomycin. Neither ADIs nor MRLs were allocated to chloramphenicol or to flumequine due to insufficient data. Additional data were not available on ronidazole, so the temporary ADI was not extended. The Committee concluded that residues resulting from the use of olaquindox in pigs under conditions of good practice in the use of veterinary drugs were temporarily acceptable, pending the submission of the results of requested residue studies.

34 The assessment of antimicrobial activity was carefully considered. The Expert Committee concluded that such activity should be assessed in all cases when antimicrobial agents are reviewed and that, in some cases, antimicrobial activity may be an appropriate endpoint for establishing an ADI. The Committee was aware that methods for examining microbiological endpoints were under development. Until these methods have been developed further, the Committee decided to remain flexible in its approach to establishing ADIs for residues of antimicrobial drugs.

35 The JECFA, in its report, provided guidance on the need for relevant and timely data for assessing the human food safety of residues of veterinary drugs and discussed risk assessment procedures that it used (see Agenda Item 5).

36 The Chairman of the Forty-second meeting of JECFA, Dr. J. Boisseau, pointed out that this was the first chance to implement the "Old Drug" policy that was developed at the Fortieth meeting. The Expert Committee found that the application of general principles to such drugs was difficult and assessments had to be performed on a case-by-case basis.

37 The Committee (CCRVDF) was informed that FAO and WHO were planning on convening two JECFA meetings per year, one of which would be dedicated to the evaluation of veterinary drugs, as recommended at the 7th Session of the CCRVDF. Future meetings on veterinary drug residues were planned for November 1994 (43rd meeting), June 1995 (45th) and June 1996 (47th). To better coordinate with CCRVDF Sessions, JECFA meetings on veterinary drug residues were planned to be convened each February from the 48th meeting onwards, which was scheduled to be held in February 1997.

IMPLEMENTATION OF RISK ASSESSMENT PROCEDURES (Agenda Item 5)

38 The CAC at its 20th Session, July 1993, had discussed a paper entitled Risk Assessment Procedures Used by the Codex Alimentarius Commission and its Subsidiary and Advisory Bodies (ALINORM 93/37) prepared by a consultant, Dr. S. Hathaway (New Zealand). The CAC had welcomed the recommendations contained in this paper and had asked that the paper be sent to all relevant Codex Committees for review and discussion. The Committee had before it the paper cited above, document CX/RVDF 94/5 containing extracts from the
The Committee supported the principles of the Hathaway paper and the view that the establishment of MRLs for residues of veterinary drugs should continue to be linked to the risk-based ADI (Acceptable Daily Intake). In this regard the Committee noted that its procedures and those of JECFA were in general consistent with the principles enunciated in the paper.

The Committee also agreed in principle that the use of risk analysis procedures should be extended further in the Codex Procedures for the elaboration of standards. Some delegations were of the opinion that the roles of the expert committees and the Codex committees in regard to risk assessment and risk management respectively should be clarified. However, it was noted that overall Codex procedures had to take into account those Committees such as Food Hygiene and Meat Hygiene which did not receive independent external expert advice on a regular basis.

The Committee expressed concern at the fact that the use of the various expressions used by Codex in relation to risk analysis had not been harmonized. It considered that further progress would be greatly assisted by having agreed Definitions for Codex purposes. It recommended to the Executive Committee that such definitions be elaborated as a matter of priority in accordance with the new Accelerated ("Fast-Track") Procedure with a view to their adoption by the CAC at its 21st Session. The Committee proposed that the definitions contained in Appendix IX to the present report should be sent to governments for comments and also considered by other relevant Codex Committees. It emphasized that any definitions adopted by the Commission should be harmonized to the extent possible with those of other relevant international organizations, for example, the OIE.

CONSIDERATION OF DRAFT MAXIMUM RESIDUE LIMITS FOR VETERINARY DRUGS AT STEP 7 (Agenda Item 6)

The Committee had before it the following documents: ALINORM 93/31A Appendix III, containing Draft MRLs held at Step 7; ALINORM 93/31A Appendix IV, containing Draft MRLs advanced from Step 5 to Step 6 by the 20th Session of the CAC; CX/RVDF 94/7 to which was attached the summary and conclusions of the 42nd meeting of JECFA; CX/RVDF 94/6, containing the comments of Norway, Spain and Thailand in response to Codex CL 1993/24-RVDF; and Conference Room Document 5, containing the comments of the European Community. It was agreed to discuss the Draft MRLs substance by substance.

Sulfadimidine

It was noted that MRLs for sulfadimidine had been held at Step 7 by the Sixth Session of the Committee pending re-evaluation by JECFA (ALINORM 93/31, paragraph 31). The Committee noted that the 42nd meeting of JECFA had allocated a full ADI of 0-50 μg/kg body weight and had confirmed the previously established MRLs for sulfadimidine in meat, liver, kidney, fat and milk when expressed as the parent drug. The Chairman of the 42nd JECFA noted that the MRLs had been confirmed at these levels in order to take account of possible allergic responses even though the ADI had been raised.

The Committee advanced the MRLs for sulfadimidine as presented in Appendix II of this report to Step 8 of the Procedure for consideration by the Commission. The draft MRLs based on total residue of the drug were deleted.

Flubendazole and Thiabendazole

The Committee advanced the MRLs for these substances as presented in Appendix II of this report to Step 8 of the Procedure for consideration by the Commission. It was noted that the EC, while not opposing the

---

advancement of the MRLs to Step 8, would review the conclusions of JECFA to determine whether to implement them within the EC.

Triclabendazole

The Committee noted that further data related to toxicity and total residues distribution and depletion were likely to become available in the near future. Pending the review of these data by JECFA, the Committee retained the MRLs for triclabendazole, as contained in Appendix III of this report, at Step 7 of the Procedure.

Isometamidium

The Committee advanced the MRLs for isometamidium as presented in Appendix II of this report to Step 8 of the Procedure for consideration by the Commission. The Committee was informed that use of this substance was not foreseen in the European Community and that it was therefore not subject to Council Regulation (EEC) 2377/90. The establishment of MRLs by the EC for this substance was not foreseen.

Bovine Somatotropins (BST)

The Committee advanced the MRLs for the bovine somatotropins as contained in Appendix II of this report to Step 8 of the Procedure for consideration by the Commission.

The Committee was informed that there was a moratorium on the licensing of BST in the EC until the end of 1994. While not objecting to advancing the MRLs for BST to Step 8, the EC could not take a formal position at the present time in regard to the adoption of these MRLs.

CONSIDERATION OF PROPOSED DRAFT MAXIMUM RESIDUE LIMITS FOR VETERINARY DRUGS AT STEP 4 ARISING FROM THE 42ND JECFA (Agenda Item 7)

The Committee had before it document CX/RVDF 94/7 which contained Summary and Conclusions of the 42nd JECFA. In response to CX/RVDF 94/7, only Poland had sent a comment stating that the Polish food legislation provided zero tolerance for residues of veterinary drugs in food.

Levamisole

The MRLs for levamisole had been retained at Step 4 by the 7th Session of the CCRVDF because the ADI and the MRLs had been temporary. The 42nd JECFA had recommended a full ADI and full MRLs for muscle, kidney, fat and liver in cattle, sheep, pigs and poultry (see Appendix IV). However, the 42nd JECFA had not considered the temporary MRL for milk (cattle) (see Appendix V) and had been unable to recommend an MRL for eggs.

The Delegation of Germany, speaking on behalf of the EC, stated that the EC had set provisional MRLs of 10 μg/kg for levamisole for muscle, kidney, liver, fat and milk for all food producing animals. These would expire on 1 January 1995 and the EC would be reviewing its MRLs in the light of the JECFA recommendations. In the meantime, the EC would not oppose the advancement of the recommended MRLs for levamisole to Step 5. The Committee agreed to advance the Proposed Draft MRLs recommended by the 42nd JECFA for muscle, kidney, fat and liver for cattle, sheep, pigs and poultry to Step 5 and to retain the temporary MRL for milk (cattle) at Step 4 pending future review by JECFA.

Diminazene

The 42nd JECFA had allocated a full ADI and full MRLs for muscle, liver, kidney and milk for cattle (see Appendix IV). The Committee noted that although some of the MRLs appeared to be relatively high, the bioavailability of diminazene in man was very low. The Committee was informed that diminazene was not foreseen to be used in the EC and was not subject to Council Regulation (EEC) 2377/90.
The Committee agreed to advance the Proposed Draft MRLs for muscle, liver, kidney and milk of cattle to Step 5.

**Spectinomycin and Dexamethasone**

The Committee noted that the 42nd JECFA had recommended temporary MRLs for spectinomycin and dexamethasone (see Appendix V) and agreed to retain these MRLs at Step 4.

**Chloramphenicol, Flumequine and Ronidazole**

The Committee noted that chloramphenicol, flumequine and ronidazole should be added to the "inactive list" (see Appendix VI). It also noted that in the event of trade disputes over compounds in the "inactive list", no Codex MRL was available. However, if appropriate data became available for any of these compounds, manufacturers and/or countries should contact the JECFA Secretariat to seek its evaluation. The Committee further noted that human exposure to medical or veterinary uses of chloramphenicol could be quite different. For example, short-term exposure for medical reasons might be desirable in certain cases, whereas involuntary exposure via residues in food was likely to cause concern.

**METHODS OF ANALYSIS AND SAMPLING FOR RESIDUES OF VETERINARY DRUGS IN FOOD**

(Agenda Item 8)

The Committee had before it Conference Room Document 1, *Report to the Plenary Session of the Seventh Meeting of the Ad Hoc Working Group on Methods of Analysis and Sampling*. A total of 57 delegates and observers from 20 countries attended the meeting. The Chairman, Dr. Richard Ellis (USA), introduced the report.

Rapporteurs were appointed to evaluate methods of analysis for residues of three veterinary drugs for which MRLs had been recommended by the 42nd meeting of JECFA and methods of analysis were discussed for 17 substances.

The Committee agreed to adopt the following Working Group recommendations:

1. that the *ad hoc* Working Group should be allowed to continue its work for the CCRVDF;
2. that member governments continue efforts to provide validated methods to the *ad hoc* Working Group for review for those veterinary drugs with recommended MRLs;
3. that sponsors are encouraged to make available analytical methods for compounds on the present and future JECFA agendas;
4. that in coordination with the Codex Committee on Pesticide Residues, the Codex Committee on Methods of Analysis and Sampling and CCRVDF continue in developing valid guidelines for methods of sampling and analysis;
5. that provisional status be given for methods for ivermectin in liver and triclabendazole in muscle, liver and kidney; and
6. that full recommendation status be given to the multiresidue method for febantel, fenbendazole and oxfendazole for all tissues and species, and for sulfadimidine in muscle tissue.

The Committee discussed the Conference Room Document 4 on the *Consideration of Greater Harmonization between Setting MRL and Availability of Routine Methods*, prepared by Australia. It asked Australia to revise the document in the light of the points raised, in particular the concern expressed about the recommendation that JECFA should set the MRL within the sensitivity achievable. The Committee asked the Working Group to consider the revised document at its next meeting so that the paper could be considered with the Working Group recommendations at the next Plenary Session of the CCRVDF.
The Committee noted the concerns of the Working Group regarding the recommendations of the Codex Committee on Methods of Analysis and Sampling that two documents related to methods evaluation be adopted by the Commission for Codex purposes (see para. 12 above and ALINORM 95/23, paras. 34-43 and Appendix V). The Working Group had expressed concern at the possibility of finding a sufficient number of laboratories to comply with the recommended criteria foreseen in the CCMAS protocol.

On a related matter, the Working Group had also expressed concern at the problems of making the methods of analysis endorsed by the Committee available to the scientific community and especially to regulatory control laboratories. The Committee encouraged the use of the ISO Layouts for Standards - Part 2: Standard for Chemical Analysis (ISO 78/2-1982), and requested that methods be submitted in this format for consideration by the Committee.

The Committee thanked the Working Group, its Chairman and the rapporteur for the report and agreed that Dr. Richard Ellis (USA) should continue as Chairman of the ad hoc Working Group.

**PRIORITY LIST OF VETERINARY DRUGS REQUIRING EVALUATION (Agenda Item 9)**

The Committee had before it Conference Room Document 2, the report of the Ad Hoc Working Group on Priorities, and CX/RVDF 94/9, a paper prepared by COMISA (Consultation Mondiale de l'Industrie de la Santé Animale) which included proposed revised criteria for the inclusion of veterinary drugs in the priority list. The Chairman of the Working Group, Dr. J. Owusu (Australia), introduced the report and recommendations.

Formal nominations for substances to be placed on the priority list were received from Australia, Belgium, and Brazil. Australia recommended porcine somatotropin, cypermethrin, and α-cypermethrin, Belgium recommended diclazuril, and Brazil recommended nicarbazin. Thailand requested that oxytetracycline and oxolinic acid be placed on the priority list for consideration of maximum residue limits (MRLs) for the giant prawn (*Penaeus monodon*). Commitments had been made for provision of relevant data on these veterinary drugs.

Nominations were made at the Working Group meeting for clenbuterol (United Kingdom), doramectin (United States of America and European Community), and abamectin, thiamphenicol, tilmicosin, and xylazine (European Community). Although it was believed that data would be made available on all of these substances, there was a need to follow up on these substances to ensure that this would be the case. COMISA made the commitment to assist in this effort.

A list had been sent by Egypt to the Chairman of the Working Group requesting that certain drugs be placed on the priority list. However, little information on availability of data was provided, and most of the drugs had already been considered by JECFA, so none of these drugs was added to the priority list.

Of the drugs listed above, abamectin, cypermethrin, and α-cypermethrin have pesticidal as well as veterinary drug uses. Both abamectin and cypermethrin had been evaluated by JMPR (Joint FAO/WHO Meeting on Pesticide Residues). The Codex definition of *pesticide* includes ectoparasiticides, so the definition might have to be changed if substances used for this purpose were to be considered veterinary drugs. While theoretically it should not make much difference whether the toxicological evaluation of such substances is performed by JECFA or JMPR, the Committee believed that it was appropriate that JECFA, rather than JMPR, reviewed the residue data for veterinary uses.

On the basis of the above considerations, the Committee agreed that the following substances should be added to the priority list:
70 The tentative agendas for the forty-third (November 1994), forty-fifth (June 1995), and forty-seventh (June 1996) meetings of JECFA are listed in Appendix VII. The agendas include substances that require re-evaluation for a number of reasons, including requests made at the present session of the CCRVDF and drugs scheduled for re-evaluation by JECFA. Abamectin, diclazuril, and doramectin, three drugs listed above, were placed on the agenda of the forty-fifth meeting of JECFA because the manufacturers indicated that data could be submitted in a timely fashion and because it would be more efficient to evaluate abamectin and doramectin along with moxidectin, which had been already on the agenda. The Delegation of Italy, after asking for clarification on the priority-setting process, requested that thiamphenicol be reviewed at the forty-fifth meeting. The proposal was not accepted because no clear indication was presented by the EC that data could be made available in time. Dexamethasone was on the agenda of the forty-third meeting for consideration of residues in horses and of the forty-seventh meeting to consider methods of analysis. The Secretariat emphasized the fact that the final agendas of JECFA were the responsibility of the Directors-General of FAO and WHO.

Criteria for the Inclusion of Substances in the Priority List

71 The Committee noted a COMISA proposal to change the criteria for placing veterinary drugs on the priority list and a proposal for introducing a weighting system for the criteria. The COMISA proposal to introduce a weighting system was not considered further as a backlog of substances to be reviewed by JECFA no longer existed. The Working Group had proposed some changes in the criteria outlined by COMISA, and additional changes were made by the Committee. The Committee considered whether specific reference should be made to the presence of residues arising from the use of the drugs when these residues could result in trade problems or public health problems, but concluded that such specific reference was not necessary. The Committee agreed to include a specific reference to public health. The Committee also noted that the obligation to provide a complete dossier conforming with the present criteria on either toxicological or residues studies could create difficulties for developing countries when proposing substances for inclusion in the priority list.

72 The revised criteria as contained in Appendix VIII were adopted by the Committee and would be submitted to the Commission for adoption to replace the earlier criteria used by the Committee (ALINORM 87/31, paras. 148-162).

73 The Committee thanked the Working Group, the Chairman, and the rapporteur for the report and decided to endorse the continuation of the ad hoc Working Group on Priorities under the Chairmanship of the Delegation of Australia.

PROGRESS REPORT ON COMPENDIUM OF VETERINARY DRUGS (Agenda Item 10)

74 The Committee noted that at its 7th Session (ALINORM 93/31A, paras. 56-58), it had been agreed that the United States would present a progress report at the 8th Session of the CCRVDF. The Delegation of the United States reported that with the collaboration of 77 countries and international organizations the revised 4th edition of Compendium of Regulations and Authorities for Registered Veterinary Products had been prepared and published both in electronic form and hard copy. Both documents were made available to all delegations at the Session. The Delegation of the United States expressed its willingness to continue this work and to expand the availability of the Compendium through computer network such as Internet.

75 The Delegation of Malaysia thanked the United States for preparing the Compendium and reported that Malaysia was using this document regularly. The Delegation, however, noted that there were certain
differences in regulatory responsibilities in Malaysia compared with other countries. The Delegation of the United States informed the Committee that consideration could be given, if necessary, to changes in the format of the Compendium if the necessary information was provided.

76 The Committee thanked the United States and unanimously requested the United States to continue this work.

OTHER BUSINESS AND FUTURE WORK (Agenda Item 11)

77 The Delegation of Israel raised concerns about the principle of the EC reserving its position within the CCRVDF or slowing the advancement of MRLs recommended by JECFA when different MRLs were adopted by the EC. Israel requested that the scientific criteria underlying the EC's position be made available in advance of future meetings.

Medium-Term Programme of Work

78 The Committee had before it CX/RVDF 94/2, which contained Medium-Term Objectives by Programme Area as Appendix I and the Committee's current status of work as Annex 1 of Appendix I.

79 The Secretariat informed the Committee that as indicated in CX/RVDF 94/2, all Codex Committees had been requested by the Commission to consider their medium-term objectives as a standing agenda item. A report on the current status of the work of the CCRVDF should be made to the Executive Committee to be reviewed in the light of the medium-term objectives. The Secretariat highlighted those medium-term objectives relevant to the CCRVDF, namely, contaminants (including residues of veterinary drugs) and risk assessment. The Committee was asked to consider these objectives and future work relevant to the objectives.

80 The Committee noted that the subject 187 "Process by Which MRLVDs are Adopted by the Commission" had been incorporated into and superseded by the subject 126 assigned for the CCGP, "Role of Science in Codex Decision-Making Process", and, therefore, the subject 187 should be deleted from the list. The Delegation of Australia, supported by several countries, proposed that the Committee should discuss "Injection Site Residues of Veterinary Drugs" and offered to prepare a working paper for consideration by the next session of the Committee. The EC reported that it was considering the same topic and the Committee requested that Australia should liaise with the EC in the preparation of a paper for the next Plenary Session of the CCRVDF. The Committee was also informed that the Working Group on Methods of Analysis and Sampling would discuss "Availability of Standards" and "Consideration of Greater Harmonization between Setting MRL and Availability of Routine Methods" at its next meeting.

DATE AND PLACE OF NEXT SESSION (Agenda Item 12)

81 The Committee was informed that its Ninth Session was tentatively scheduled for 24-27 October 1995 held in Washington, D.C., with the working group meetings held on Monday, 23 October.

82 Noting the high priority given by the CCRVDF to the clarification of "Role of Science" in Codex Procedures, the Secretariat was requested to consider all possible options to schedule a meeting of the CCGP before the 21st Session of the Commission in July 1995. If it was found necessary, the next session of the CCRVDF should be postponed to accommodate the CCGP Session in early 1995. The Committee hoped that this would be unnecessary in the light of concerns expressed by some delegations about the delays in advancing MRLs for compounds already in the system and arising from the two forthcoming JECFA meetings. If it was inevitable, however, the date of the next CCRVDF Session would be determined after the consultation between the United States and the Secretariat.
## SUMMARY STATUS OF WORK

<table>
<thead>
<tr>
<th>Subject</th>
<th>Step</th>
<th>For Action by</th>
<th>Document Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Draft Maximum Residue Limits for Veterinary Drugs</td>
<td>8</td>
<td>21st CAC</td>
<td>ALINORM 95/31, Appendix II</td>
</tr>
<tr>
<td>Proposed Draft Maximum Residue Limits for Veterinary Drugs</td>
<td>5</td>
<td>21st CAC</td>
<td>ALINORM 95/31, Appendix IV</td>
</tr>
<tr>
<td>Draft Maximum Residue Limits for Veterinary Drugs</td>
<td>7</td>
<td>JECFA CCRVDF</td>
<td>ALINORM 95/31, Appendix III</td>
</tr>
<tr>
<td>Proposed Draft Maximum Residue Limits for Veterinary Drugs</td>
<td>4</td>
<td>JECFA CCRVDF</td>
<td>ALINORM 95/31, Appendix V</td>
</tr>
<tr>
<td>Priority List of Veterinary Drugs Requiring Evaluation</td>
<td>1</td>
<td>41st Executive Committee</td>
<td>ALINORM 95/31, Appendix VII</td>
</tr>
<tr>
<td>Risk Analysis Definitions</td>
<td>1</td>
<td>41st Executive Committee</td>
<td>ALINORM 95/31, para. 41 and Appendix IX</td>
</tr>
<tr>
<td>Draft Criteria for the Inclusion in, or Exclusion from, the Priority List</td>
<td>-</td>
<td>21st CAC</td>
<td>ALINORM 95/31, paras. 71-72 and Appendix VIII</td>
</tr>
<tr>
<td>Methods of Analysis and Sampling</td>
<td>-</td>
<td>Governments CCRVDF</td>
<td>ALINORM 95/31, paras. 57-62, 80</td>
</tr>
<tr>
<td>List of Veterinary Drugs Evaluated by JECFA on Which No Action Has Been Taken by the Committee</td>
<td>-</td>
<td>Governments</td>
<td>ALINORM 95/31, Appendix VI</td>
</tr>
<tr>
<td>Injection Site Residues of Veterinary Drugs</td>
<td>-</td>
<td>Australia, EC 9th CCRVDF</td>
<td>ALINORM 95/31, para. 80</td>
</tr>
<tr>
<td>Consideration of Greater Harmonization between Setting MRL and Availability of Routine Methods</td>
<td>-</td>
<td>Australia WG on Methods of Analysis and Sampling</td>
<td>ALINORM 95/31, para. 60</td>
</tr>
<tr>
<td>Progress Report on Compendium of Veterinary Drugs</td>
<td>-</td>
<td>United States</td>
<td>ALINORM 95/31, paras. 74-76</td>
</tr>
</tbody>
</table>
Appendix I

LIST OF PARTICIPANTS
LISTE DES PARTICIPANTS
LISTA DE PARTICIPANTES

Chairman: Dr. Stephen Sundlof
Président: Director
Presidente: Center for Veterinary Medicine
Food and Drug Administration
HFV-1, MPN-2, 7500 Standish Place
Rockville, MD 20855, USA

Rapporteur: Dr. J. Michael Rutter
Director of Veterinary Medicines and
Chief Executive
Veterinary Medicines Directorate
Woodham Lane, New Haw, Addlestone
Surrey, KT15, 3NB, U.K.

Assistant to the Chairman: Dr. Sharon R. Thompson
Adjoint du Président: Special Assistant to the Director
Asistente del Presidente: Center for Veterinary Medicine
Food and Drug Administration
HFV-3, MPN-2, 7500 Standish Place
Rockville, MD 20855
USA

2 The Heads of Delegations are listed first.
Les chefs de délégation figurent en tête.
Figuran en primer lugar los Jefes de las delegaciones.
ARGENTINA
ARGENTINE

Dr. Alfredo Montes Nino
Unión de la Industria Carnica
Argentina-UNICA
Av. de Mayo 981-2nd Floor
Buenos Aires, Argentina

Mr. Mariano E. Ripari
Embassy of Argentina
Office of Agricultural Affairs
1600 New Hampshire Avenue, NW.
Washington, DC  20009
USA

AUSTRALIA
AUSTRALIE

Dr. James (Jack) Y. Haslam
Veterinary Counsellor
Australian Embassy
1601 Massachusetts Ave., NW.
Washington, DC  20036
USA

Mr. Kerryn McDougall
Special Chemist
NSW Agriculture
Wollongbar Agricultural Institute
Bruxner Highway
Wollongbar, NSW, 2480
Australia

Mr. Ron Hogg
Regional Director
Australian Government Analytical Laboratories (WA)
PO Box 83
Cottesloe, WA, 6011
Australia

Dr. Norman Blackman
Director, National Residue Survey
PO Box E11
Queen Victoria Terrace
Canberra, ACT, 2600
Australia

Mr. Richard Game
Executive Officer
Agricultural and Veterinary Chemicals Policy Section
Department of Primary Industries and Energy
GPO Box 858
Canberra, ACT, 2600
Australia

Mr. Ian Wells
Rural Consultant
Oakhill
Hausmann Road
Mt Mee, Qld 4521
Australia

Dr. John Owusu
National Registration Authority
P.O. Box 240
Queen Victoria Terrace, Parkes
ACT 2600
Australia

Mr. Ian J. Douglas
AVCARE Limited
Private Bag 938
North Sydney NSW 2059
Australia

**BELGIUM**
**BELGIQUE**
**BELGICA**

Prof. Dr. M. Debackere (Head of Delegation)
Faculty of Veterinary Medicine
University of Ghent
Ministry of Public Health
Casinoplein 24
B-9000 Ghent - Belgium

Dr. Marc Cornelis
Inspecteur - Expert
Ministère de la Santé Publique
Institut de l'Expertise Vétérinaire
Rue de la Loi, 56
1040 Brussels, Belgium

Dr. William Vandaele
AGIM
"BVD Consultants" S A
Av Chevalier Jehan 87
B-1300 Wavre
Belgium

**BRAZIL**
**BRESIL**
**BRASIL**

Mr. Manuel Montenegro (Head of Delegation)
Head, Science and Technology Section
Brazilian Embassy
3006 Massachusetts Ave., N.W.
Washington, DC  20008
USA

Dr. Nelson Chachamovitz
1st Vice President
National Veterinary Industry Association
Av. Brig. Faria Lima 1409-141°
01451-905 - Sao Paulo - SP
Brazil

CANADA

Dr. M. S. Yong, Chief
Human Safety Division
Bureau of Veterinary Drugs
Food Directorate
Health Protection Branch
Health Canada
Main Statistics Building, Room 2605
Ottawa, Ontario
Canada K1A OL2

Dr. J.D. MacNeil
Head, Food Animal Chemical Residues
Health of Animals Laboratory
Agriculture and Agri-Food Canada
116 Veterinary Road
Saskatoon, Saskatchewan
S7N 2R3
Canada

Ms. Jean E. Szkotnicki
Executive Director
Canadian Animal Health Institute
27 Cork St. W.
Guelph, Ontario, NIH 2W9
Canada

CHINA, PEOPLE'S REPUBLIC OF
CHINE, REPUBLIQUE POPULAIRE DE
CHINA, REPUBLICA POPULAR DE

Dr. Jinglan Feng
Deputy Director
Department of Animal Husbandry and Health
Ministry of Agriculture
No. 11 Nongzhanguan Nanli
100026 Beijing, P.R. China

Ms. Chen Yuying
Deputy Director
State Administration of Import and Export Commodity Inspection of P.R.C.
15 Fangcaode W. Rd.
Beijing 100020
China
Ms. Sun Zhaofen  
Director  
Tianjin Import and Export Commodity Inspection Bureau of P.R. China  
6 Pu Kou Dao Hexi District  
Tianjin 300042  
China

Dr. Chao-Kuang Hsu  
President of Shared Enterprises  
Advisor to the Ministry of Agriculture of P.R. China  
280 Stonegate Drive  
Devon, PA 19333  
China

Mrs. Guo Wenlin  
Assistant Researcher of China National Institute for the Control of Veterinary and Bioproducts and Pharmaceuticals  
No. 30 Baishiqiao Road  
Beijing, P.R. China

Mr. Li Jinxiang  
Division Chief  
Department of Animal Husbandry and Health  
Ministry of Agriculture  
No. 11 Nongzhanguan Nanli  
100026 Beijing, P.R. China

COSTA RICA

Mr. José Luis Rojas M.  
Chief of Toxicology and Residues Section  
Laboratorio Nacional de Servicios Veterinarios  
Ministerio Agricultura y Gañaderia  
Costa Rica

DENMARK  
DANEMARK  
DINAMARCA

Mr. Torben Westfahl  
Master of Science  
Danish Veterinary Service  
Food Control Laboratory  
Odinsvej 4  
Postboks 93  
DK-4100 Ringsted  
Denmark

Mr. Milter Green Lauridsen  
Senior Chemist  
National Food Agency of Denmark  
Morkhoj Bygade 19  
DK-2860 Soborg  
Denmark
EGYPT
EGYPTE
EGIPTO

Dr. Mustafa M. Haykal
General Director of Veterinary Services
Ministry of Agriculture
Mailing Address: Wizarat El Ziraa Street
Dokki, Giza, Egypt

Dr. Ibrahim M. Antar
Agricultural Minister-Counselor
Embassy of Egypt
Washington, DC
USA

FINLAND
FINLANDE
FINLANDIA

Dr. Jorma Hirn
National Veterinary and Food Research Institute
P.O. Box 368
SF-00231 Helsinki
Finland

Dr. Timo Hirvi
National Veterinary and Food Research Institute
P.O. Box 368
SF-00231 Helsinki
Finland

FRANCE
FRANCIA

Monsieur J. Boisseau
Ministère de L'Agriculture et de la Forêt - CNEVA
Laboratoire des Médicaments Vétérinaires
La Haute-Marche
Javene 35133 Fougères
France

Mr. Claude Meurier
Ministère de l'Agriculture et de la Forêt
Directeur Général du CNEVA
22 rue Pierre Curie
94700 Maisons Alfort Cedex
Paris
France

Mr. Guy E. Milhaud
Professor Alfort Veterinary School
Conseil Supérieur de l'Ordre des Vétérinaires
68, rue du Rendez-vous
75012 Paris
France
Mr. Honore Carré
Inspecteur Général
D.G.C.C.R.F. - DNE
79 boulevard du Montparnasse
75272 Paris Cedex 06
France

Monsieur Monsallier Georges
S.I.M.V.
6, rue de la Tremoille
75008 Paris
France

Dr. Gilles Le Lard
Direction générale de l'Alimentation
Rue du Chevaleret
75013 Paris
France

Dr. Daniel Jeanclaude
Directeur, Division Vétérinaire
Laboratoires Janssen
17, rue de l'Ancienne-Marie
92513 Boulogne-Billancourt Cedex, France

GERMANY
ALLEMAGNE
ALEMANIA

Dr. Heinrich Botterman
Ministry of Health
Am Probsthof 78a
53121 Bonn
Germany

Prof. Dr. Reinhard Kroker
Federal Health Office - Berlin
and Director of the Robert-von-Ostertag-Institut

Dr. Martin Schneidereit
Federal Association for Animal Health
Aennchenplatz 6
53173 Bonn
Germany

Dr. Rainer Malisch
State Institute for Chemical Analysis of Food
Bissierstr, 5
D-79114 Freiburg
Germany

Dr. Alexander Boettner
HOECHST VETERINAR GMBH
Rheingaustrasse 190
D-65203 Wiesbaden
Germany

INDONESIA
INDONESIE

Dr. Sofian Sudradjat
Director of Animal Health Development
Director General of Livestock
Ministry of Agriculture, Indonesia
JL. Salemba Raya 16
Jakarta, Indonesia

Mr. P. Natigor Siagian
Agricultural Attaché
Embassy of Indonesia
2020 Massachusetts Avenue, NW.
Washington, DC 20036
USA

IRELAND
IRLANDE
IRLANDA

Mr. Sean O'Connor
Deputy Director, Veterinary Services
Department of Agriculture, Food and Forestry
Kildare Street
Dublin 2
Ireland

Dr. Cyril O'Sullivan
Chief Executive
National Drugs Advisory Board
Charles Lucas House
63/64, Adelaide Road
Dublin, 2
Ireland

ISRAEL

Dr. Stefan Soback
Head, National Residue Control Laboratory
Ministry of Agriculture
Kimron Veterinary Institute
P.O. Box 12
50250 Beit Dagan
Israel

ITALY
ITALIE
ITALIA

Dr. Livia Tosato
Scientific Attaché
Embassy of Italy
1061 Fuller Street, NW
Washington, DC 20009
USA

JAPAN
JAPON

D.V. M. Noriko Iseki
Technical Official
Veterinary Sanitation Division
Environmental Health Bureau
Ministry of Health and Welfare
Japan

Dr. Kazuo Suzuki
Deputy Director
Pharmaceutical Affairs Office
Animal Health Division
Bureau of Livestock Industry
Ministry of Agriculture
Forestry and Fisheries
Japan

Dr. Mariko Okada
Chief Research Scientist
Division of Analytical Chemistry
Research Institute for Animal Science in Biochemistry and Toxicology
Japan

Dr. Yoshitaka Yonehara
Director
Japan Veterinary Pharmaceutical Association
Japan

Dr. Hiroshi Tachi
Technical Adviser
Japan Veterinary Pharmaceutical Association
Japan

Mr. Hideki Tarumi
First Secretary
Health and Welfare
Embassy of Japan
2620 Massachusetts Ave., NW.
Washington, DC  20008
USA

REPUBLIC OF KOREA
REPUBLICA DE COREA
REPUBLICA DE COREA

Dr. Jong Myung Park
Director, Residue and Toxicology Div.
Veterinary Research Institute
Rural Development Administration
#480, Anyang 6 Dong, Anyang City
Gyunggi Do, 430-016
Republic of Korea

Dr. Joo Ho Lee
Assistant Director, Animal Health Div.
Livestock Bureau
Ministry of Agriculture, Forestry & Fisheries
#1, Choongang Dong, Kwacheon City
Gyunggi Do, 427-760
Republic of Korea

Dr. Byoung Gon Jeong
Veterinary Officer
National Animal Quarantine Service
# san 23-4, Tunchon Dong, Kangso Gu
Seoul City, 157-030
Republic of Korea

Dr. Jae Gil Yeh
Member, Technical Committee of Korea Animal Health Products Assoc.
Room 627, Medium Industry Building
# 16-2, Youido Dong, Yongdungpo Gu
Seoul City, 150-010
Republic of Korea

LEBANON
LIBAN
LIBANO

Mr. Jad El-Hassan
Counsellor
Embassy of Lebanon
2560 28th Street, NW.
Washington, DC  20008
USA

MADAGASCAR

Dr. Biclar H.G. Andrianantoandro
Economic and Commercial Counselor
Embassy of Madagascar
2374 Massachusetts Ave., NW.
Washington, DC  20008
USA

MALAYSIA
MALAISIE
MALASIA

Dr. Anwar Hassan
Assistant Director General (Animal Health)
Department of Veterinary Services
Block A, 8 & 9 Floor, Exchange Square
Off Jalan Semantan
50630 Kuala Lumpur, Malaysia
Ms. Martha Chávez Niño  
Subdirector de Servicios a la Industria  
Dirección General de Salud Animal  
Dirección de Servicios y Registros Zoosanitarios  
Recreo N° 51  
Col. Actipan del Valle  
C.P. 03230 México D.F.

Mrs. Dr. Cornelia Loesberg  
Head of the Department of Veterinary Medicines  
Ministry of Agriculture, Nature Management and Fisheries  
Veterinary Service  
P.O. Box 20401  
2500 EK The Hague  
Netherlands

Dr. William F. Droppers  
Ministry of Welfare, Health and Cultural Affairs  
Food and Product Safety Directorate  
P.O. Box 3008  
2280 MK Rijswijk  
Netherlands

Dr. Jos H. Goebbels  
Ministry of Welfare, Health and Cultural Affairs  
Veterinary Public Health Inspectorate  
P.O. Box 5406  
2280 HK Rijswijk  
Netherlands

Dr. Rainer W. Stephany  
National Institute of Public Health and Environmental Protection  
Head, Laboratory for Residue Analysis  
P.O. Box 1  
3720 BA Bilthoven  
Netherlands

D. W. Lunn  
Registrar, Pesticides Board  
Agricultural Compounds Unit  
Ministry of Agriculture and Fisheries  
P.O. Box 40063  
Upper Hutt, New Zealand

Dr. Barry L. Marshall
Counsellor (Veterinary Services)
New Zealand Embassy
37 Observatory Circle, NW.
Washington, DC  20008
USA

NORWAY
NORVEGE
NORUEGA

Mr. Magne Yndestad, Professor
Dept. of Pharmacology, Microbiology and Food Hygiene
Norwegian College of Veterinary Medicine
P.O. Box 8146 Dep.
N-0033 Oslo, Norway

Mr. Sverre O. Roald
Regional Chief Inspector
Directorate of Fisheries
Dept. of Quality Control
P.O. Box 168
N-6001 Alesund, Norway

POLAND
POLOGNE
POLONIA

Dr. Jan Zmudzki, DVM, PhD.
Professor and Head
Dept. of Pharmacology and Toxicology
National Veterinary Research Institute
Partyzantow 57
24-100 Pulawy, Poland

PORTUGAL

Prof. Dr. Eduardo Fontes
Instituto Da Proteccao Da Producao Agro-Alimentar
Largo Nacional Da Academia das Belas Artes
#2 1200 Lisboa
Portugal

Dr. Maria Ponte
Instituto Da Proteccao Da Producao Agro-Alimentar
Largo Nacional Da Academia das Belas Artes
#2 1200 Lisboa
Portugal
Dr. I. Teveloiu  
Deputy General Director of the Veterinary Division  
Ministry of Agriculture and Food  
Bucharest, Romania

Dr. Stephan B. Kurylas  
1807 Blue Ridge Avenue  
Wheaton, MD 20902  
USA

Dr. Odon Sobrino  
Ministerio de Agricultura, Pesca y Alimentación  
Subdirección General de Sanidad Animal  
Servicio de Medicamentos Veterinarios  
C/Velazquez, 147  
28002 Madrid  
Spain

Mr. Paul Anders Manestam  
Chief Government Veterinary Inspector  
National Food Administration  
Box 622  
S-751 26 UPPSALA  
Sweden

Dr. Hakan Johnsson  
Head of Chemistry Division 3  
National Food Administration  
Box 622  
S-751 26 UPPSALA  
Sweden

Dr. H. Koch (Head of Delegation)  
Swiss Federal Veterinary Office  
Schwarzenburgstrasse 161  
CH-3097 Liebefeld  
Switzerland
Dr. Josef Schlatter  
Federal Office of Public Health  
c/o Institute of Toxicology  
Schorenstrasse 16  
CH-8603 Schwerzenbach  
Switzerland

Dr. Roland Charriere  
Federation of Migros Cooperatives  
Meat Laboratory  
CH-1784 Courtepin  
Switzerland

Dr. Jean A. Vignal  
NESTEC Ltd  
Avenue Henri Nestlé, 55  
CH-1800 Vevey  
Switzerland

THAILAND  
THAILANDE  
TAILANDIA

Miss Brisit Karunyavanij  
Expert in Medical Scientist  
Department of Medical Sciences  
(Ministry of Public Health)  
Yod-Se, Bangkok 10100  
Thailand

Dr. Yuantar Pruksaraj  
Director, Feed Quality Control Division  
Dept. of Livestock Development  
Phayathai Road  
Bangkok 10400  
Thailand

Dr. Ganjanee Thampipattanakul  
Veterinary Public Health Division  
Department of Livestock Development  
Phayathai Road  
Bangkok 10400  
Thailand

Mr. Warawudh Chuwiruch  
First Secretary  
Royal Thai Embassy  
Washington, DC  
USA

Mrs. Usa Kolkasing  
Standards Officer 6  
Thai Industrial Standards Institute  
Ministry of Industry  
Thailand
Dr. Wirachal Panichnantak  
Feed Registrations Officer  
Feed Quality Control Division  
Dept. of Livestock Development  
Phayathai Road  
Bangkok 10400  
Thailand

TUNISIA  
TUNISIE

Dr. Abdelhamid Hannachi  
Veterinary Doctor  
Directorate of Environmental Hygiene and Protection of the Environment  
Ministry of Public Health

UNITED KINGDOM  
ROYAUME-UNI  
REINO UNIDO

Dr. Kevin Nicholas Woodward  
Director of Licensing  
Veterinary Medicines Directorate  
Woodham Lane, New Haw, Addlestone  
Surrey, KT15 3NB, U.K.

Dr. J. Michael Rutter  
Director of Veterinary Medicines and Chief Executive  
Veterinary Medicines Directorate  
Woodham Lane, New Haw, Addlestone  
Surrey, KT15 3NB, U.K.

Dr. George Shearer  
Head, Veterinary Drug Residues Section  
CSL Food Science Laboratory  
Norwich Research Park  
Colney  
Norwich, NR4 7UQ, U.K.

Dr. Anthony J. Mudd  
Technical Manager  
Cyanamid of Great Britain Ltd.  
Fareham Road, Gosport  
Hampshire PO13 OAS  
United Kingdom
UNITED STATES OF AMERICA
ETATS-UNIS D'AMERIQUE
ESTADOS UNIDOS DE AMERICA

Dr. Marvin A. Norcross
Executive Assistant to the Administrator
Food Safety and Inspection Service
U.S. Department of Agriculture
Room 2151, South Building
14th and Independence Ave., SW.
Washington, DC  20250
USA

Dr. Robert C. Livingston
Director, Office of New Animal Drug Evaluation, HFV-100
Center for Veterinary Medicine
Food and Drug Administration
7500 Standish Place, Rm. 389
Rockville, MD  20855
USA

Government Advisors:

Dr. Richard A. Carnevale
Assistant Deputy Administrator for Scientific Operations
USDA, FSIS, Science and Technology
300 12th Street, SW., Room 405-Annex
Washington, DC  20250
USA

Dr. Richard Ellis
Director, Chemistry Division
USDA, FSIS, Science and Technology
300 12th Street, SW., Room 603-Annex
Washington, DC  20250
USA

Dr. Richard Mikita
Export Advisor
International Programs
USDA, Food Safety & Inspection Service
Room 0207, South Building
14th & Independence Avenue, SW.
Washington, DC  20250
USA

Dr. Harless A. McDaniel
Assistant to the Deputy Administrator for Veterinary Services
APHIS, USDA
Presidential Building, Room 268
6505 Belcrest Road
Hyattsville, MD  20782
USA

Dr. Richard Talbot
Virginia Polytechnic Institute and State University College of Veterinary Medicine
Phase II, Duck Pond Drive  
Blacksburg, VA  24061  
USA  

Dr. John O'Rangers  
Office of New Animal Drug Evaluation (HFV-100)  
Center for Veterinary Medicine  
Food and Drug Administration  
7500 Standish Place, Room 389  
Rockville, MD  20855  
USA  

Mr. Jeffrey L. Brown  
Executive Secretary  
USDA, FSIS, Science and Technology  
300 12th Street, SW.  
Room 409 - Annex Building  
Washington, DC  20250  
USA  

Non-Government Members:  

Dr. Martin K. Terry  
Vice President, Scientific and International Affairs  
Animal Health Institute  
501 Wythe Avenue  
Alexandria, VA  22314  
USA  

Ms. Diane E. Frazer  
Director, Regulatory Affairs  
Pitman-Moore, Inc.  
421 E. Hawley Street  
Mundelein, IL  60060  
USA  

Dr. Gerald B. Guest  
19105 Plummer Drive  
Germantown, MD  20876  
USA  

Dr. Robert Jorgensen  
Governmental Relations Division  
American Veterinary Medical Association  
1101 Vermont Avenue, NW.  
Suite 710  
Washington, DC  20005  
USA
Dr. Gordon Kemp
Director of Science Policy Affairs
Pfizer, Inc.
Eastern Point Road
Groton, CT 06340
USA

Mr. C. W. McMillan
Consultant
P.O. Box 10009
Alexandria, VA 22310-0009
USA

Dr. John Modderman
Keller and Heckman
1001 G Street, NW.
Suite 500 W
Washington, DC 20001
USA

Dr. Donald Ingle
Manager, International Animal Regulatory Affairs
American Cyanamid Company
P.O. Box 400
Princeton, NJ 08543-0400
USA

Dr. Larry C. Pendlum
Director, Regulatory Affairs
Lilly Research Laboratories
2001 W. Main Street
P.O. Box 708
Greenfield, IN 46170
USA

Dr. Rainer K. Muser
Director, Product Development and Registration
Hoechst-Roussel Agri-Vet Company
Routes 202-206 North
Somerville, NJ 08876
USA

OBSERVER COUNTRIES
PAYS OBSERVATEURS
PAISES OBSERVADORES

PUERTO RICO
PORTO RICO

Mr. Herni Horta Cruz
Assistant Secretary of Environmental Health
Health Department
Call Box 70184
San Juan, PR 00936
Puerto Rico
INTERNATIONAL ORGANIZATIONS
ORGANISATIONS INTERNATIONALES
ORGANIZACIONES INTERNACIONALES

AOAC INTERNATIONAL (AOAC)

Ms. Lucyna Kurtyka
Methods Coordinator
AOAC International
2200 Wilson Blvd., Suite 400
Arlington, VA  22201-3301
USA

Mr. George Heavner
Technical Coordinator
AOAC International
2200 Wilson Blvd., Suite 400
Arlington, VA  22201-3301
USA

EUROPEAN COMMUNITIES (EC)

Dr. Barbara Röstel-Peters
D.G. III/E/3, "Pharmaceuticals"
European Commission
Rue de La Loi 200
1049 Brussels, Belgium

Dr. Claire Gaudot
Administrateur Principal, DG VI B II/2
European Commission
86 Rue de la Loi 7/36
1049 Brussels, Belgium

Mr. Bent Mejborn
Council Secretariat of the European Union
170, Rue de la Loi
1048 Brussels, Belgium

INTERNATIONAL DAIRY FEDERATION (IDF)

Prof. Dr. Walther H. Heeschen, Director
Federal Dairy Research Centre
Institute of Hygiene
Postfach 6069
D-24121 Kiel
Germany
OFFICE INTERNATIONAL DES EPIZOOTIES (OIE)

Mr. Jacques Boisseau
Directeur du Laboratoire National des Médicaments Vétérinaires
Javene
35133 Fougères
France

WORLD CONSULTATION OF THE ANIMAL HEALTH INDUSTRY (COMISA)

Dr. Peter Altreuther
President of COMISA
Rue Defacqz 1 Bte 8
B-1050 Brussels
Belgium

Dr. David J.S. Miller
Executive Secretary
c/o Sandoz Pharmaceuticals Ltd.
Frimley Business Park
Frimley, Camberley
Surrey GU 16 55G, U.K.

Mr. Richard H. Ekfelt
President
Animal Health Institute
P.O. Box 1417-D50
Alexandria, VA  22313
USA

Dr. Christian Verschueren
Secretary General of COMISA and
Director, Technical and Int'l. Affairs of FEDESA
Rue Defacqz 1, Bte 8
B-1050 Brussels
Belgium

Ms. Brigitte Biedermann
Administration Manager, COMISA
Rue Defacqz 1, Bte 8
B-1050 Brussels
Belgium

Mr. Dennis Erpelding
Manager, Government Relations
Elanco Animal Health
1101 Pennsylvania Ave., NW.
Suite 540
Washington, DC  20004
USA
Dr. William Horton  
Group Leader Residue Chemistry  
American Cyanamid Company  
Agricultural Research Division  
P.O. Box 400  
Princeton, NJ  08543-0400  
USA

Dr. C. Patrick Moore  
Manager, Latin American Development  
Mallinckrodt Veterinary, Inc.  
421 E. Hawley Street  
Mundelein, IL  60060  
USA

Ms. Sandra L. Phelan  
Manager, Animal Drug Section  
Animal Health Institute  
P.O. Box 1417-D50  
Alexandria, VA  22313  
USA

Dr. Isabelle Demade  
Director, Government and Public Affairs, Europe  
SmithKline Beecham  
Avenue Louise 287/13  
1050 Brussels  
Belgium

Dr. Marcel Rogiers  
Senior Vice-President Animal Health  
Janssen Pharmaceutica N.V.  
Turnhoutseweg 30  
B-2340 Beerse  
Belgium

Dr. Brian Bagnall  
Vice President, Government and Public Affairs  
SmithKline Beecham Animal Health  
1600 Paoli Pike  
West Chester, PA  19380  
USA

Dr. Chandralal Weerasinghe  
Manager, Drug Metabolism and Environmental Safety  
SmithKline Beecham Animal Health  
1600 Paoli Pike  
West Chester, PA  19380  
USA
Dr. Raul J. Guerrero  
Latin American Federation of Animal Health (FILASA)  
c/o Lilly Research Laboratories  
P.O. Box 708  
Greenfield, Indiana 46140  
USA

Mr. Richard J. Wyse  
Latin American Federation of Animal Health (FILASA)  
H. Yrigoyen 850  
Buenos Aires, Argentina

Dr. John Augsburg  
Global Animal Regulatory Affairs  
American Cyanamid Company  
P.O. Box 400  
Princeton, NJ 08543-0400  
USA

INTERNATIONAL ORGANISATION OF CONSUMERS UNIONS (IOCU)

Mr. Mark Silbergeld  
Consumers Union  
Suite 310  
1666 Connecticut Avenue, NW.  
Washington, DC 20009  
USA

PAN AMERICAN HEALTH ORGANIZATION (PAHO)

Dr. Claudio R. Almeida  
Regional Advisor for Food Protection  
Pan American Health Organization  
525 Twenty-Third Street, N.W.  
Washington, DC 20037-2895  
USA

FOOD AND AGRICULTURE ORGANIZATION OF THE UNITED NATIONS (FAO)

Dr. Juhani Paakkanen  
Food Control Officer  
Food Quality Liaison Group  
Food Policy and Nutrition Division  
FAO  
Via delle Terme di Caracalla  
00100 Rome, Italy
WORLD HEALTH ORGANIZATION (WHO)

Dr. John L. Herrman  
International Programme on Chemical Safety  
World Health Organization  
1211 Geneva 27  
Switzerland

Dr. P. Chamberlain  
World Health Organization  
1211 Geneva 27  
Switzerland

JOINT FAO/WHO SECRETARIAT

Dr. Alan Randell  
Senior Officer  
Joint FAO/WHO Food Standards Programme  
Food and Agriculture Organization of the United Nations  
Via delle Terme di Caracalla  
00100 Rome, Italy

Dr. Yukiko Yamada  
Food Standards Officer  
Joint FAO/WHO Food Standards Programme  
Food and Agriculture Organization of the United Nations  
Via delle Terme di Caracalla  
00100 Rome, Italy

UNITED STATES SECRETARIAT

Ms. Rhonda S. Nally  
Executive Officer for Codex Alimentarius  
FSIS, Room 2151-South Building  
U.S. Department of Agriculture  
14th and Independence Ave., SW.  
Washington, DC 20250  
USA

Ms. Patty L. Woodall  
Staff Assistant for Codex Alimentarius  
FSIS, Room 2151-South Building  
U.S. Department of Agriculture  
14th and Independence Ave., SW.  
Washington, DC 20250  
USA
Ms. Kathy R. LaQuay  
Program Assistant  
FSIS, Room 2151-South Building  
U.S. Department of Agriculture  
14th and Independence Ave., SW.  
Washington, DC  20250  
USA  

Ms. Margaret Klock  
Office of the Director  
Center for Veterinary Medicine (HFV-1)  
Food and Drug Administration  
7500 Standish Place  
Rockville, MD  20855, USA  

Ms. Natalie Zalc  
Secretary  
USDA/FSIS/OA - Rm. 2151-South Bldg.  
14th and Independence Ave., SW.  
Washington, DC  20250  
USA  

SPECIAL LISTING:  

Ms. Patricia Jensen  (Guest Speaker)  
Assistant Secretary for Marketing and Inspection Services  
U.S. Department of Agriculture  
Room 228-W, Administration Bldg.  
14th and Independence Ave., SW.  
Washington, DC  20250  
USA  

Ms. Joan M. Mondschein  
Confidential Assistant  
U.S. Department of Agriculture  
FSIS - Room 2151-South Building  
14th and Independence Ave., SW.  
Washington, DC  20250  
USA  

Lester M. Crawford, DVM, PhD  
Executive Director  
Association of American Veterinary Medical Colleges  
1101 Vermont Avenue, NW  
Suite 710  
Washington, DC  20005-3521  
USA
DRAFT MAXIMUM RESIDUE LIMITS FOR VETERINARY DRUGS
(Advanced to Step 8 of the Procedure)

NOTE: Section 5 - Reference to JECFA Reports - contains references to the reports of meetings of the Joint FAO/WHO Expert Committee on Food Additives, as published in the WHO Technical Report Series (TRS). Relevant toxicological monographs are published in the WHO Food Additives Series (FAS) and residue monographs of the substances concerned are published in the FAO Food and Nutrition Paper (FNP) Series.

1. **Substance: Sulfadimidine**

2. Acceptable Daily Intake (ADI) as established by JECFA 0-50 μg/kg body weight

3.1(a) Commodity (a)Muscle, liver, kidney and fat

     (b)MRL (b) 100 μg/kg

     (c)Definition of residue on which MRL was set (c)sulfadimidine

3.2(a) Commodity (a)Milk (cattle)

     (b)MRL (b) 25 μg/l

     (c)Definition of residue on which MRL was set (c)sulfadimidine

4. References to recommended method(s) of analysis

   (a) *Journal of the Association of Official Analytical Chemists* 66 (1983) 881, 884
   (b) *Journal of Agricultural and Food Chemistry* 29 (1981) 621-624

5. Reference to JECFA Reports

   WHO TRS 788 (1989)
   WHO TRS 815 (1991)
   WHO FAS 25 (1990)
   FAO FNP 41/2 (1990)
   WHO TRS (to be published)
   WHO FAS 33 (1994)
   FAO FNP 41/6 (1994)

6. Reference to previous Codex reports

   Appendix III, ALINORM 91/31
   Appendix III, ALINORM 91/31A
   Appendix III, ALINORM 93/31
   Appendix III, ALINORM 93/31A

---
1. **Substance: Flubendazole**

2. Acceptable Daily Intake (ADI) as established by JECFA

3. (a) Commodity
   (b) MRL
   (c) Definition of residue on which MRL was set

3.1 (a) Muscle and liver (pigs)
   (b) 10 μg/kg
   (c) flubendazole

3.2 (a) Muscle (poultry)
   (b) 200 μg/kg
   (c) flubendazole

3.3 (a) Liver (poultry)
   (b) 500 μg/kg
   (c) flubendazole

3.4 (a) Eggs
   (b) 400 μg/kg
   (c) flubendazole

4. References to recommended method(s) of analysis


5. Reference to JECFA Reports

   WHO TRS 832 (1993)
   WHO FAS 31 (1992)
   FAO FNP 41/5 (1992)

6. Reference to previous Codex reports

   Appendix IV, ALINORM 91/31A

---

1. **Substance: Thiabendazole**

2. Acceptable Daily Intake (ADI) as established by JECFA

3. (a) Commodity
   (b) MRL

3.1 (a) Muscle, liver, kidney, fat (cattle, pigs, goats, sheep); Milk (cattle, goats)
   (b) 100 μg/kg
1. **Substance:** Isometamidium

2. Acceptable Daily Intake (ADI) as established by JECFA

   0-100 μg/kg body weight

3.1(a) Commodity

   (a) Muscle, fat, milk (cattle)

   (b) MRL

   (b) 100 μg/kg

   (c) Definition of residue on which MRL was set

   (c) isometamidium

3.2(a) Commodity

   (a) Liver (cattle)

   (b) MRL

   (b) 500 μg/kg

   (c) Definition of residue on which MRL was set

   (c) isometamidium

3.3(a) Commodity

   (a) Kidney (cattle)

   (b) MRL

   (b) 1000 μg/kg

   (c) Definition of residue on which MRL was set

   (c) isometamidium

4. References to recommended method(s) of analysis

   **Mignot, A., Lefebvre, M., and Vidal, R.** Determination of isometamidium concentration in plasma and tissue samples of young bulls after intramuscular administration of trypanidium at a level of 1 mg.kg⁻¹. Unpublished report submitted to FAO by Rhone Merieux, Toulouse Cedex, France (1991)

5. Reference to JECFA Reports

   WHO TRS 832 (1993)
   WHO FAS 31 (1992)
   FAO FNP 41/5 (1992)

6. Reference to previous Codex reports

   Appendix IV, ALINORM 91/31A
1. **Substance**: Bovine Somatotropins

2. Acceptable Daily Intake (ADI) as established by JECFA  
   Not specified\(^1\)

3.1(a) Commodity  
   (a) Muscle, fat, liver, kidney, milk (cattle)

   (b) MRL  
   (b) Not specified\(^2\)

   (c) Definition of residue on which MRL was set  
   (c) Not applicable

4. References to recommended method(s) of analysis  
   Torkelson, A.R., Dwyer, K.A., and Rogan, G.J.  
   Radioimmunoassay of somatotropin in milk from cows administered recombinant bovine somatotropin Abstract,  
   *J. Dairy Sci.*, 70 (Suppl. 1) (1987), 146

5. Reference to JECFA Reports  
   WHO TRS 832 (1993)  
   WHO FAS 31 (1992)  
   FAO FNP 41/5 (1992)

6. Reference to previous Codex reports  
   Appendix IV, ALINORM 91/31A

---

\(^1\) ADI "not specified" is a term applicable to a veterinary drug for which there is a large margin of safety for the consumption of its residues based on available toxicity and margin of safety for the consumption of its residues based on available toxicity and intake data when the drug is used according to good practice in the use of veterinary drugs. For that reason, and for the reasons stated in the individual evaluation, the Committee has concluded that use of the veterinary drug does not represent a hazard to human health and that there is no need to specify a numerical acceptable daily intake.

\(^2\) MRL "not specified" is a term applicable to a veterinary drug for which there is a large margin of safety for the consumption of its residues based on available data on the identity and concentration of the residues in animal tissues when the drug is used according to good practice in the use of veterinary drugs. For that reason, and for the reasons stated in the individual evaluation, the Committee has concluded that the presence of drug residues in the indicated animal product does not present a health concern and that there is no need to specify a numerical maximum residue limit.
DRAFT MAXIMUM RESIDUE LIMITS FOR VETERINARY DRUGS
(Retained at Step 7 of the Procedure)

NOTE: Section 5 - Reference to JECFA Reports - contains references to the reports of meetings of the Joint FAO/WHO Expert Committee on Food Additives, as published in the WHO Technical Report Series (TRS). Relevant toxicological monographs are published in the WHO Food Additives Series (FAS) and residue monographs of the substances concerned are published in the FAO Food and Nutrition Paper (FNP) Series.

1. **Substance: Triclabendazole**

2. Acceptable Daily Intake (ADI) as established by JECFA

   0-3 μg/kg body weight

3.1(a) Commodity

   (a) Muscle (cattle)

   (b) MRL

   (b) 200 μg/kg

   (c) Definition of residue on which MRL was set

   (c) 5-chloro-6-(2',3'-dichlorophenoxy)-benzimidazole-2-one

3.2(a) Commodity

   (a) Liver, kidney (cattle)

   (b) MRL

   (b) 300 μg/kg

   (c) Definition of residue on which MRL was set

   (c) 5-chloro-6-(2',3'-dichlorophenoxy)-benzimidazole-2-one

3.3(a) Commodity

   (a) Fat (cattle);
   Muscle, liver, kidney, fat (sheep)

   (b) MRL

   (b) 100 μg/kg

   (c) Definition of residue on which MRL was set

   (c) 5-chloro-6-(2',3'-dichlorophenoxy)-benzimidazole-2-one

4. References to recommended method(s) of analysis

   (a) Marti, A.M., Mooser, A.E., and Koch. H.
   Determination of Benzimidazole Antihelmintics in Meat Samples, *J. Chromatog.*, **498** (1990), 145-157

5. Reference to JECFA Reports

   WHO TRS 832 (1993)
   WHO FAS 31 (1992)
   FAO FNP 41/5 (1992)

6. Reference to previous Codex reports

   Appendix IV, ALINORM 93/31A
NOTE: Section 5 - Reference to JECFA Reports - contains references to the reports of meetings of the Joint FAO/WHO Expert Committee on Food Additives, as published in the WHO Technical Report Series (TRS). Relevant toxicological monographs are published in the WHO Food Additives Series (FAS) and residue monographs of the substances concerned are published in the FAO Food and Nutrition Paper (FNP) Series.

1. **Substance: Levamisole**

2. Acceptable Daily Intake (ADI) as established by JECFA
   - 0-6 μg/kg body weight

3.1(a) Commodity
   - (a) Muscle, kidney, fat (cattle, sheep, pigs, poultry)
   (b) MRL
   - (b) 10 μg/kg
   (c) Definition of residue on which MRL was set
   - (c) levamisole

3.2(a) Commodity
   - (a) Liver (cattle, sheep, pigs, poultry)
   (b) MRL
   - (b) 100 μg/kg
   (c) Definition of residue on which MRL was set
   - (c) levamisole

4. References to recommended method(s) of analysis
   - (To be elaborated)

5. Reference to JECFA Reports
   - WHO TRS 799 (1990)
   - WHO TRS In preparation
   - WHO FAS 27 (1991)
   - WHO FAS 33 (1994)
   - FAO FNP 41/3 (1990)
   - FAO FNP 41/6 (1994)

6. Reference to previous Codex reports
   - Appendix II, ALINORM 91/31A
   - Appendix V, ALINORM 93/31A
1. **Substance: Diminazene**

2. Acceptable Daily Intake (ADI) as established by JECFA  
   0-100 μg/kg body weight

3.1(a) Commodity  
   (a) Muscle (cattle)

(b) MRL  
   (b) 500 μg/kg

(c) Definition of residue on which MRL was set  
   (c) diminazene

3.2(a) Commodity  
   (a) Liver (cattle)

(b) MRL  
   (b) 12 000 μg/kg

(c) Definition of residue on which MRL was set  
   (c) diminazene

3.3(a) Commodity  
   (a) Kidney (cattle)

(b) MRL  
   (b) 6 000 μg/kg

(c) Definition of residue on which MRL was set  
   (c) diminazene

3.4(a) Commodity  
   (a) Milk (cattle)

(b) MRL  
   (b) 150 μg/l

(c) Definition of residue on which MRL was set  
   (c) diminazene

4. References to recommended method(s) of analysis  
   (to be elaborated)

5. Reference to JECFA Reports  
   WHO TRS In preparation
   WHO FAS 33 (1994)
   FAO FNP 41/6 (1994)

6. Reference to previous Codex reports  
   None

---

1 Limit of quantitation of the analytical method.
NOTE: Section 5 - Reference to JECFA Reports - contains references to the reports of meetings of the Joint FAO/WHO Expert Committee on Food Additives, as published in the WHO Technical Report Series (TRS). Relevant toxicological monographs are published in the WHO Food Additives Series (FAS) and residue monographs of the substances concerned are published in the FAO Food and Nutrition Paper (FNP) Series.

<table>
<thead>
<tr>
<th>1. <strong>Substance:</strong> Levamisole</th>
</tr>
</thead>
<tbody>
<tr>
<td>2. Acceptable Daily Intake (ADI) as established by JECFA</td>
</tr>
<tr>
<td>3.1(a) Commodity</td>
</tr>
<tr>
<td>(b) MRL</td>
</tr>
<tr>
<td>(c) Definition of residue on which MRL was set</td>
</tr>
<tr>
<td>4. References to recommended method(s) of analysis</td>
</tr>
<tr>
<td>5. Reference to JECFA Reports</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>6. Reference to previous Codex reports</td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>

1. **Substance:** Carazolol

| 2. Acceptable Daily Intake (ADI) as established by JECFA | 0-0.1 μg/kg body weight (Temporary) |
| 3.1(a) Commodity | (a) Muscle and fat (cattle and pigs) |
| (b) MRL | (b) 5 μg/kg (Temporary) |
| (c) Definition of residue on which MRL was set | (c) carazolol |
3.2(a) Commodity (a)Liver and kidney (cattle and pigs)
(b)MRL (b) 30 μg/kg (Temporary)
(c)Definition of residue on which MRL was set (c)carazolol

4. References to recommended method(s) of analysis
   Rose, M.D. and Shearer, G.  *J. Chromatography* 624 (1992) 471-477 (Liver and Kidney)

5. Reference to JECFA Reports
   WHO TRS 815 (1991)
   WHO FAS 29 (1991)
   FAO FNP 41/4 (1991)

6. Reference to previous Codex reports
   Appendix V, ALINORM 93/31A

1.  **Substance: Spiramycin**

2. Acceptable Daily Intake (ADI) as established by JECFA
   0-5 μg/kg body weight (Temporary)

3.1(a) Commodity (a)Muscle (cattle and pigs)
   (b)MRL (b) 50 μg/kg (Temporary)
   (c)Definition of residue on which MRL was set (c)spiramycin

3.2(a) Commodity (a)Liver (cattle and pigs)
   (b)MRL (b) 300 μg/kg (Temporary)
   (c)Definition of residue on which MRL was set (c)spiramycin

3.3(a) Commodity (a)Kidney (cattle and pigs)
   (b)MRL (b) 200 μg/kg (Temporary)
   (c)Definition of residue on which MRL was set (c)spiramycin
3.4(a) Commodity
(a) Milk (cattle)
(b) MRL
(b) 150 μg/l (Temporary)
(c) Definition of residue on which MRL was set
(c) spiramycin

4. References to recommended method(s) of analysis
(to be elaborated)

5. Reference to JECFA Reports
WHO TRS 815 (1991)
WHO FAS 29 (1991)
FAO FNP 41/4 (1991)

6. Reference to previous Codex reports
Appendix V, ALINORM 93/31
Appendix V, ALINORM 93/31A

1. **Substance: Febantel**

2. Acceptable Daily Intake (ADI) as established by JECFA
0-10 μg/kg body weight (Temporary)

3.1(a) Commodity
(a) Muscle, fat, kidney, (cattle, pigs, sheep)
(b) MRL
(b) 100 μg/kg (Temporary) (Group MRL)¹
(c) Definition of residue on which MRL was set
(c) oxfendazole sulfone

3.2(a) Commodity
(a) Liver (cattle, pigs, sheep)
(b) MRL
(b) 500 μg/kg (Temporary) (Group MRL)¹
(c) Definition of residue on which MRL was set
(c) oxfendazole sulfone

3.3(a) Commodity
(a) Milk (cattle)
(b) MRL
(b) 100 μg/l (Temporary) (Group MRL)¹
(c) Definition of residue on which MRL was set
(c) oxfendazole sulfone

4. References to recommended method(s) of analysis
See Thiabendazole, Appendix II

5. Reference to JECFA Reports
WHO TRS 815 (1991)
WHO FAS 29 (1991)
FAO FNP 41/4 (1991)

6. Reference to previous Codex reports
Appendix V, ALINORM 93/31
Appendix V, ALINORM 93/31A
1. **Substance: Fenbendazole**

2. Acceptable Daily Intake (ADI) as established by JECFA

   0-25 μg/kg body weight (Temporary)

3.1(a) Commodity

   (a) Muscle, fat, kidney, (cattle, pigs, sheep)

   (b) MRL

   (b) 100 μg/kg (Temporary) (Group MRL)¹

   (c) Definition of residue on which MRL was set

   (c) oxfendazole sulfone

3.2(a) Commodity

   (a) Liver (cattle, pigs, sheep)

   (b) MRL

   (b) 500 μg/kg (Temporary) (Group MRL)¹

   (c) Definition of residue on which MRL was set

   (c) oxfendazole sulfone

3.3(a) Commodity

   (a) Milk (cattle)

   (b) MRL

   (b) 100 μg/l (Temporary) (Group MRL)¹

   (c) Definition of residue on which MRL was set

   (c) oxfendazole sulfone

4. References to recommended method(s) of analysis

   See Thiabendazole, Appendix II

5. Reference to JECFA Reports

   WHO TRS 815 (1991)
   WHO FAS 29 (1991)
   FAO FNP 41/4 (1991)

6. Reference to previous Codex reports

   Appendix V, ALINORM 93/31
   Appendix V, ALINORM 93/31A

---

1. **Substance: Oxfendazole**

2. Acceptable Daily Intake (ADI) as established by JECFA

   0-4 μg/kg body weight (Temporary)

3.1(a) Commodity

   (a) Muscle, fat, kidney, (cattle, pigs, sheep)

   (b) MRL

   (b) 100 μg/kg (Temporary) (Group MRL)¹

   (c) Definition of residue on which MRL was set

   (c) oxfendazole sulfone

3.2(a) Commodity

   (a) Liver (cattle, pigs, sheep)

   (b) MRL

   (b) 500 μg/kg (Temporary) (Group MRL)¹
1. **Substance: Spectinomycin**

2. Acceptable Daily Intake (ADI) as established by JECFA

3.1(a) Commodity (a) Muscle (cattle, pigs, chickens)

(b)MRL (b) 300 µg/kg (Temporary)

(c)Definition of residue on which MRL was set (c)spectinomycin

3.2(a) Commodity (a)Liver (cattle, pigs, chickens)

(b)MRL (b) 2 000 µg/kg (Temporary)

(c)Definition of residue on which MRL was set (c)spectinomycin

3.3(a) Commodity (a)Kidney (cattle, pigs, chickens)

(b)MRL (b) 5 000 µg/kg (Temporary)

(c)Definition of residue on which MRL was set (c)spectinomycin

3.4(a) Commodity (a)Fat (cattle, pigs, chickens)

(b)MRL (b) 500 µg/kg (Temporary)

(c)Definition of residue on which MRL was set (c)spectinomycin
1. **Substance: Dexamethasone**

2. Acceptable Daily Intake (ADI) as established by JECFA

   0-0.015 μg/kg body weight

3.1(a) Commodity

   (a)Muscle, kidney (cattle, pigs)

   (b)MRL

   (b) 0.5 μg/kg (Temporary)

   (c)Definition of residue on which MRL was set

   (c)dexamethasone

3.2(a) Commodity

   (a)Liver (cattle, pigs)

   (b)MRL

   (b) 2.5 μg/kg (Temporary)

   (c)Definition of residue on which MRL was set

   (c)dexamethasone

3.3(a) Commodity

   (a)Milk (cattle)

   (b)MRL

   (b) 0.3 μg/l (Temporary)

   (c)Definition of residue on which MRL was set

   (c)dexamethasone

4. References to recommended method(s) of analysis

   (to be elaborated)

5. Reference to JECFA Reports

   WHO TRS In preparation
   WHO FAS 33 (1994)
   FAO FNP 41/6 (1994)

6. Reference to previous Codex reports

   None

---

1. Group MRL for febantel, fendendazole and oxfendazole individually or in combination. The MRL value is the sum of the residues of fenbendazole, oxfendazole and oxfendazole sulfone calculated as oxfendazole sulfone.
**LIST OF VETERINARY DRUGS EVALUATED BY JECFA ON WHICH NO ACTION HAS BEEN TAKEN BY THE COMMITTEE**

**NOTE:** The current list indicates those substances evaluated by JECFA for which no maximum residue level could be recommended by the Expert Committee. The most usual reason for not establishing an MRL was the inadequacy of data provided to JECFA for evaluation. However, it is essential to consult the Expert Committee report for a full understanding of the status of the substance concerned.

<table>
<thead>
<tr>
<th>Substance</th>
<th>JECFA Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Azaperone</td>
<td>38th Session, TRS 815 (1991)</td>
</tr>
<tr>
<td>Chloramphenicol</td>
<td>42nd Session, TRS In Preparation</td>
</tr>
<tr>
<td>Chlorpromazine</td>
<td>38th Session, TRS 815 (1991)</td>
</tr>
<tr>
<td>Dimetridazole</td>
<td>34th Session, TRS 788 (1989)</td>
</tr>
<tr>
<td>Flumequine</td>
<td>42nd Session, TRS In Preparation</td>
</tr>
<tr>
<td>Furazolidone</td>
<td>40th Session, TRS 832 (1993)</td>
</tr>
<tr>
<td>Ipronidazole</td>
<td>34th Session, TRS 788 (1989)</td>
</tr>
<tr>
<td>Metronidazole</td>
<td>34th Session, TRS 788 (1989)</td>
</tr>
<tr>
<td>Nitrofurazone</td>
<td>40th Session, TRS 832 (1993)</td>
</tr>
<tr>
<td>Propionylpromazine</td>
<td>38th Session, TRS 815 (1991)</td>
</tr>
<tr>
<td>Ractopamine</td>
<td>40th Session, TRS 832 (1993)</td>
</tr>
<tr>
<td>Ronidazole</td>
<td>42nd Session, TRS In Preparation</td>
</tr>
<tr>
<td>Sulfathiazole</td>
<td>34th Session, TRS 788 (1989)</td>
</tr>
<tr>
<td>Tylosin</td>
<td>38th Session, TRS 815 (1991)</td>
</tr>
</tbody>
</table>
PRIORITY LIST OF VETERINARY DRUGS
REQUIRING EVALUATION OR REEVALUATION

1. Substances scheduled for consideration at the 43rd meeting of JECFA in November 1994

   Azaperone *
   Carazolol *
   Dexamethasone (residues) *
   Dihydrostreptomycin
   Enrofloxacin
   Gentamicin
   Neomycin
   Oxolinic acid
   Spiramycin *
   Streptomycin

2. Substances scheduled for consideration at the 45th meeting of JECFA in June 1995

   Abamectin
   Ceftiofur Sodium
   Chlortetracycline
   Diclazuril
   Doramectin
   Febantel *
   Fenbendazole *
   Levamisole (residues) *
   Moxidectin
   Oxfendazole *
   Oxytetracycline (giant prawns - residues)
   Tetracycline
   Triclabendazole *

3. Substances proposed for consideration at the 47th meeting of JECFA in June 1996

   Alpha cypermethrin
   Cypermethrin (residues)
   Clenbuterol
   Dexamethasone (methodology)*
   Imidocarb
   Nicarbazin
   Olaquindox (residues)*
   Porcine Somatotropin
   Spectinomycin (residues)*
   Thiamphenicol
   Thiabendazole (toxicology)*
   Tilmicosin
   Xylazine

   * reevaluation

Note: Of all the substances on the CCRVDF Priority List, only apramycin is not scheduled for review by JECFA.
DRAFT CRITERIA FOR THE INCLUSION IN, OR EXCLUSION FROM, THE PRIORITY LIST
(Submitted to the Commission for adoption)

In order to be placed on the CCRVDF's priority list for the development of a maximum residue limit, the candidate veterinary drug, when used in accordance with good veterinary practices, should meet some, but not necessarily all, of the following criteria:

1. Use of the drug will have potential to cause public health and/or trade problems;

2. Drug available as commercial product; and

3. Commitment that a dossier will be available.
HAZARD: A biological, chemical or physical agent or property that may cause a food to be unsafe for human consumption, or a defect generally considered objectionable.

RISK: A function of the probability of an adverse event and the magnitude of that event, consequential to a hazard(s) in food.

RISK ANALYSIS: A process consisting of three components: risk assessment, risk management and risk communication.

RISK ASSESSMENT: A scientific process of identifying hazards, and estimating risk in quantitative or qualitative terms. This involves four analytical steps:

1. HAZARD IDENTIFICATION - The qualitative indication that a hazard(s) could be present in a particular food;

2. HAZARD CHARACTERIZATION - The quantitative and/or qualitative evaluation of the nature of the adverse effects, and may include a dose-response assessment;

3. EXPOSURE CHARACTERIZATION - The quantitative and/or qualitative evaluation of the degree of human exposure likely to occur;

4. RISK CHARACTERIZATION - Integration of the above steps into an estimation of the adverse effects likely to occur in a given population, including attendant uncertainty.

RISK ASSESSMENT POLICY: Pre-determined guidelines for scientific judgements and policy frameworks which may be applied at specific decision points in the risk assessment process.

QUANTITATIVE RISK ASSESSMENT: The estimation of risks as numerical representations including point estimates and/or distributions.

QUALITATIVE RISK ASSESSMENT: The estimation of risks as categorical representations including ordinal rankings, descriptive classifications, etc.

RISK MANAGEMENT: The process of weighing policy alternatives, selecting an appropriate regulatory option, and implementing that option.

RISK COMMUNICATION: An interactive process of exchange of information and opinion on risk among risk assessors, risk managers, and stakeholders.

---

3Defect: A pathological change or other abnormality.

4Dose-response assessment: The determination of the relationship between the magnitude of exposure and adverse effects.
The reference to the recommended methods of analysis for sulfadimidine* should read as follows:

4. Reference to recommended method(s) of analysis
   (b) Journal of Agricultural and Food Chemistry 29 (1981) 621-624
   (c) Malisch, R., Bourgeois, B. and Lippold R. Multiresidue Analysis of Selected Chemotherapeutics and Antiparasitics Dtsch. Lebensmittel Rundsch. 88 (1992) 205-216

* The Eighth Session of the Codex Committee on Residues of Veterinary Drugs in Foods advanced the Maximum Residue Limits for sulfadimidine to Step 8 of the Codex procedure.